No Data
No Data
No Data
Core One Labs Faces Leadership Resignation Amid Regulatory Challenges
Core One Labs Extends Private Placement
Core One Labs Initiates $1.5 Million Private Placement
Core One Labs Signs Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry Into the International Market
Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods